Finch Therapeutics Group, Inc.

Equities

FNCH

US31773D2009

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 17:48:45 23/05/2024 BST			5-day change	1st Jan Change
1.98 ^USD	-7.04%		+3.12%	-45.15%

05-10	Finch Therapeutics Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-25	Finch Therapeutics Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Finch Therapeutics Group, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

August 11, 2022 at 12:00 pm

Finch Therapeutics Group, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported revenue was USD 0.361 million compared to USD 2.83 million a year ago. Net loss was USD 22.7 million compared to USD 15.17 million a year ago. Basic loss per share from continuing operations was USD 14.4 compared to USD 9.6 a year ago.
For the six months, revenue was USD 0.715 million compared to USD 6.38 million a year ago. Net loss was USD 47.27 million compared to USD 29.15 million a year ago. Basic loss per share from continuing operations was USD 29.7 compared to USD 28.5 a year ago.

Latest news about Finch Therapeutics Group, Inc.

Finch Therapeutics Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
Finch Therapeutics Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-25	CI
Top Premarket Decliners	03-12	MT
North American Morning Briefing : Stocks Seen -2-	11-15	DJ
Finch Therapeutics Group, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08	CI
North American Morning Briefing : Stock Futures -2-	16/08/23	DJ
Finch Therapeutics Group, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23	CI
Finch Therapeutics Group, Inc. Announces Resignation of Nicholas Haft as Member of Board	23/06/23	CI
Finch Therapeutics Group, Inc.(NasdaqGS:FNCH) dropped from Russell Microcap Index	23/06/23	CI
Finch Therapeutics Group, Inc.(NasdaqGS:FNCH) dropped from Russell Microcap Value Index	23/06/23	CI
Finch Therapeutics Group, Inc.(NasdaqGS:FNCH) dropped from Russell 3000E Value Index	23/06/23	CI
Finch Therapeutics Group, Inc.(NasdaqGS:FNCH) dropped from Russell 3000E Index	23/06/23	CI
Top Premarket Decliners	13/06/23	MT
Finch Therapeutics Group Slumps Almost 15% in Premarket Tuesday	13/06/23	MT
Finch Therapeutics Group to Implement 1-for-30 Reverse Stock Split	09/06/23	MT
Finch Therapeutics Group, Inc. Enters into Lease Termination Agreement with NRL WCS 200 Inner Belt Prop, LLC	18/05/23	CI
Finch Therapeutics Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	10/05/23	CI
Earnings Flash (FNCH) FINCH THERAPEUTICS GROUP Posts Q1 Revenue $107,000	10/05/23	MT
Finch Therapeutics Group, Inc. Reports Unaudited Consolidated Impairment of Long-Lived Assets for the First Quarter Ended March 31, 2023	10/05/23	CI
Finch Therapeutics Appoints Matthew Blischak CEO, Lance Thibault CFO	26/04/23	MT
Finch Therapeutics Group, Inc. Announces Executive Leadership Transitions	25/04/23	CI
Finch Therapeutics Group, Inc. Appoints Lance Thibault as Chief Financial Officer, Effective May 16, 2023	25/04/23	CI
Finch Therapeutics Group, Inc. Announces Executive Changes	25/04/23	CI
Finch Therapeutics Reports Clinical Collaboration in Ulcerative Colitis; Shares Soar After-Hours	18/04/23	MT
Finch Therapeutics Group, Inc. Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women's Hospital and Updates to University of Minnesota License Agreement	18/04/23	CI

Chart Finch Therapeutics Group, Inc.

Duration

Period

More charts

Company Profile

Finch Therapeutics Group, Inc. is a microbiome technology company with a portfolio of intellectual property and microbiome assets. It is focused on realizing the value of its intellectual property estate and other assets, while supporting the advancement of its microbiome technology through partnerships and collaborations. It has an intellectual property estate, including more than 113 issued U.S. and foreign patents with relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. Its assets include CP101, an orally administered microbiome candidate designed for the prevention of recurrent C. difficile infection (CDI), with positive clinical data from a Phase II randomized, placebo-controlled trial and a Phase II open-label trial, and pre-clinical assets that are designed to target ulcerative colitis, Crohnâs disease, and autism spectrum disorder. Additionally, it has also developed a biorepository of strains and samples.

Sector

Biotechnology & Medical Research

More about the company

	1st Jan change	Capi.
FINCH THERAPEUTICS GROUP, INC.	-45.15%	3.42M
MODERNA, INC.	+64.54%	62.59B
IQVIA HOLDINGS INC.	-1.24%	41.18B
LONZA GROUP AG	+44.76%	40.29B
CELLTRION, INC.	-8.93%	27.9B
ICON PUBLIC LIMITED COMPANY	+13.51%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.66%	19.09B
BIO-TECHNE CORPORATION	+4.91%	13.08B
UNITED THERAPEUTICS CORPORATION	+25.57%	12.26B
MEDPACE HOLDINGS, INC.	+28.05%	12.05B

Other Biotechnology & Medical Research